Human BCR ABL (F317L) BAF3 Cell Line

Description

The BCR ABL (F317L) BAF3 Cell Line is a genetically engineered model derived from murine BAF3 parental cells. It is generated through stable expression of the human BCR ABL fusion gene harboring the F317L point mutation, integrated using lentiviral transduction. This mutation is located within the ABL kinase domain and is associated with resistance to tyrosine kinase inhibitors such as imatinib. Engineered cells are validated by qRT-PCR.
Target
The BCR-ABL fusion results from the Philadelphia chromosome translocation and encodes a constitutively active tyrosine kinase driving leukemogenesis. The F317L mutation alters the ATP-binding site, reducing sensitivity to first-generation BCR-ABL inhibitors. This cell model enables investigation of drug resistance mechanisms and evaluation of second/third-generation inhibitors. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.